KPW
LCTX icon

Kore Private Wealth’s Lineage Cell Therapeutics LCTX Stock Holding History

Kore Private Wealth’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-147
Closed – – 724
2020
Q2 		$0 Hold
147
– – ﹤0.01% 1217
2020
Q1 		$0 Hold
147
– – ﹤0.01% 1149
2019
Q4 		$0 Buy
+147
New +$122 ﹤0.01% 1058
2019
Q2 		– Sell
-147
Closed – – 542
2019
Q1 		$0 Buy
+147
New +$183 ﹤0.01% 953

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Kore Private Wealth's LCTX Position: Q3 2020 in Review

Kore Private Wealth sold out of Lineage Cell Therapeutics (LCTX) in Q3 2020, closing a stake of 147 shares.

Kore Private Wealth first reported a position in LCTX in Q1 2019 and held it in 4 quarters. The position peaked at $0 in Q2 2020. 75 funds tracked by Wall St. Rank hold LCTX as of Q3 2020.

  • Kore Private Wealth reported no remaining Lineage Cell Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 147 Lineage Cell Therapeutics shares in Q3 2020.
  • Kore Private Wealth first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 4 quarters.
  • Kore Private Wealth's Lineage Cell Therapeutics position peaked at $0 in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.